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Objective: Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In preclinical animal models, blocking activin
receptor (ACVR) ligands has improved survival and prevented muscle wasting in cancer cachexia without an effect on tumour growth. However,
the underlying mechanisms are poorly understood. This study aimed to identify cancer cachexia and soluble ACVR (sACVR) administration-evoked
changes in muscle proteome.
Methods: Healthy and C26 tumour-bearing (TB) mice were treated with recombinant sACVR. The sACVR or PBS control were administered either
prior to the tumour formation or by continued administration before and after tumour formation. Muscles were analysed by quantitative pro-
teomics with further examination of mitochondria and nicotinamide adenine dinucleotide (NADþ) metabolism. To complement the first pro-
phylactic experiment, sACVR (or PBS) was injected as a treatment after tumour cell inoculation.
Results: Muscle proteomics in TB cachectic mice revealed downregulated signatures for mitochondrial oxidative phosphorylation (OXPHOS) and
increased acute phase response (APR). These were accompanied by muscle NADþ deficiency, alterations in NADþ biosynthesis including
downregulation of nicotinamide riboside kinase 2 (Nrk2), and decreased muscle protein synthesis. The disturbances in NADþ metabolism and
protein synthesis were rescued by treatment with sACVR. Across the whole proteome and APR, in particular, Serpina3n represented the most
upregulated protein and the strongest predictor of cachexia. However, the increase in Serpina3n expression was associated with increased
inflammation rather than decreased muscle mass and/or protein synthesis.
Conclusions: We present evidence implicating disturbed muscle mitochondrial OXPHOS proteome and NADþ homeostasis in experimental
cancer cachexia. Treatment of TB mice with a blocker of activin receptor ligands restores depleted muscle NADþ and Nrk2, as well as decreased
muscle protein synthesis. These results indicate putative new treatment therapies for cachexia and that although acute phase protein Serpina3n
may serve as a predictor of cachexia, it more likely reflects a condition of elevated inflammation.
 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Cancer cachexia is a multiorgan syndrome characterised by loss of
body mass (BM) due to muscle and adipose tissue wasting in the
majority of cancer patients [1]. Tumour-derived factors and systemic
inflammation are considered the main drivers of cachexia [1].
Inflammation leads to an increase in the concentration of cytokines and
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mortality [3]. Moreover, in preclinical animal models, prevention of
cancer cachexia improved survival without effects on tumour growth
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Abbreviations
36B4 acidic ribosomal phosphoprotein P0
ACC Acetyl-CoA Carboxylase
ACVR2B-Fc activin receptor type IIB
AMPK adenosine monophosphate activated protein kinase
ANOVA analysis of variance
APP acute phase protein





COX cytochrome c oxidase
CTRL control mice
DEP differentially expressed protein
FDR false discovery rate
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GDF11 growth and differentiation factor 11
DIA nano-LC-HDMSE data independent acquisition nano-liquid
chromatography high definition tandem mass
spectrometry
DMEM Dulbecco’s Modified Eagle’s Medium
FBS fetal bovine serum
GA Gastrocnemius
HPRT hypoxanthine phosphoribosyltransferase 1






MCP-1 monocyte chemoattractant protein-1
mTORC mechanistic target of rapamycin complex
NADþ nicotinamide adenine dinucleotide
NAMPT nicotinamide phosphoribosyl transferase
NAPRT nicotinate phosphoribosyltransferase




PCA Principal Component Analysis
PGC-1a peroxisome proliferator-activated receptor gamma coactivator 1
alpha
PPARA peroxisome proliferator-activated receptor-alpha
PPARGC1A and PPARGC1B peroxisome proliferator-activated receptor gamma
coactivator 1 alpha and beta
PVDF polyvinylidene difluoride
QPRT quinolinate phosphoribosyltransferase
ROS reactive oxygen species
Rn18s 18S ribosomal RNA
RT-PCR quantitative reverse transcription polymerase chain reaction
sACVR soluble ligand binding domain of activin receptor type IIB
sACVR/b sACVR administration before tumour formation
sACVR/c continued sACVR administration before and after tumour
SDH succinate dehydrogenase
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM standard error of the mean
Serpina3n serpin family A member 3n
SIRT1 sirtuin-1
STAT3 signal transducer and activator of transcription 3




TCA cycle tricarboxylic acid cycle
TDO tryptophan 2,3-dioxygenase
TGF-b transforming growth factor-b
Original ArticleProteins from the transforming growth factor-b (TGF-b) superfamily
are cytokines, which among others are upregulated in diseases
such as cancer. For instance, the expression of TGF-b superfamily
proteins, activins A and B, is increased in many human [7] and
murine cancer cell lines and tumours [4]. Blood activin A is also
elevated in patients with cancer cachexia [8]. Activins A and B and
other TGF-b family members such as myostatin and growth and
differentiation factor 11 (GDF11) are negative regulators of muscle
mass [9e11]; they can be blocked using various strategies such as
administration of soluble ligand binding domain of their receptor,
namely, activin receptor type IIB (sACVR2B-Fc, herein referred to as
sACVR), which effectively increases muscle mass in mice [4,12e
15], and humans [16]. Blocking ACVR ligands prolongs survival
and reverses cancer cachexia in mice [4e6]. We previously
demonstrated improved survival in Colon-26 carcinoma (C26) TB-
mice with continued sACVR administration after tumour formation
but not when it was administered only before cancer engraftment to
increase muscle mass before cachexia [4]. The administration of
sACVR attenuated muscle loss in limb and respiratory muscles [4]
and improved antioxidant protection in muscle tissue of TB-mice
[17], without alterations in tumour growth and inflammation.
However, blocking ACVR-signalling did not show major effects at
either the metabolome [18] or microbiome level [19]. Thus, no
explanation has been provided for the improved survival in sACVR-
treated mice.2 MOLECULAR METABOLISM 41 (2020) 101046  2020 The Author(s). Published by Elsevier GWe applied 3 protocols to compare the impact of blocking ACVR2 li-
gands: i) administration before the tumour formation to increase
muscle size only before the onset of cachexia, ii) administration both
before and after the onset of cachexia, or iii) treatment after the tumour
is present. These comparisons were made to further understand, at the
muscle level, why improved survival was achieved when anti-cachexia
treatment was continued after tumour formation but not when it was
administered only as a preventive measure [4]. We first conducted
muscle proteomic profiling from mice bearing the C26 cancer with or
without administration of sACVR. Thereafter, we functionally validated
our results to reveal Serpina3n as a predictor of cachexia, but not a
generic marker of alterations in muscle mass, and discovered altered
nicotinamide adenine dinucleotide (NAD)þ metabolism in cancer,
which was rescued upon treatment with sACVR.
2. MATERIALS AND METHODS
2.1. Mice
Male BALB/c (BALB/cAnNCrl) mice aged 5e6 weeks (Charles River
Laboratories) were housed under standard conditions (temperature
22 C, 12:12 h light/dark cycle) with free access to food pellets (R36;
4% fat, 55.7% carbohydrate, 18.5% protein, 3 kcal/g, Labfor, Stock-
holm Sweden) and water.
The treatment of animals was in strict accordance with the European
Convention for the protection of vertebrate animals used formbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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experimental and other scientific purposes. The protocols were
approved by the National Animal Experiment Board, and experiments
were conducted in accordance with the guidelines of the committee
(permit number: ESAVI/10137/04.10.07/2014).
2.2. Tumour cell culture
C26 cells were maintained in complete Dulbecco’s Modified Eagle’s
Medium (DMEM, high glucose, GlutaMAX supplement, pyruvate,
Gibco, Life Technologies) supplemented with penicillin (100 U/mL),
streptomycin (100 mg/mL) and 10% FBS.
2.3. Experimental design
Experiment 1: mice were randomised into 1 of 4 body-weight matched
groups as described earlier [4]: 1) healthy control mice (CTRL) were
injected with PBS vehicle, 2) C26 TB-mice received vehicle adminis-
tration throughout the experiment (C26 þ PBS), 3) C26 TB-mice
received only prophylactic sACVR administration before tumour for-
mation (until day 1 after C26 cell inoculation), followed by vehicle
administration until the end of the experiment (C26þ sACVR/b), and 4)
C26 TB-mice received continued sACVR administration throughout the
experiment (C26 þ sACVR/c), namely, in a prophylactic and continued
manner.
Experiment 2: mice were randomised into either 1) CTRL (þPBS), 2)
C26 þ PBS, or 3) sACVR injected after C26 tumour engraftment
(C26 þ sACVR). The experimental design is depicted in Figure 1A.
2.4. Experimental treatments
On day 0, mice were anaesthetised by ketamine and xylazine
(Ketaminol and Rompun, respectively) and inoculated with
5  105 C26 cells in 100 ml of PBS (TB-mice) or with an equal volume
of vehicle (PBS) only (CTRL) into the intrascapular subcutis. Adminis-
tration of 100 ml of sACVR diluted in PBS (5 mg/kg) or PBS vehicle was
conducted intraperitoneally (i.p.). In experiment 1, sACVR (5 mg/kg)
was injected twice per week, 3 times before C26 cell inoculation on
days 11, 7, 3. For C26 þ sACVR/c mice, sACVR was adminis-
tered also after C26 cell inoculation, on days 1, 5, and 9. In the second
experiment, sACVR (10 mg/kg) or PBS was injected as a treatment only
on days 6 and 9 after tumour cell inoculation (Figure 1A).Figure 1: Overall study design (A). Experiment 1. Mice were inoculated with C26 cells on d
5, and 9. Muscles, liver, and blood were collected 11 days after the C26 cell inoculation. In
inoculation. Heat map representation of differential proteome changes in 3 conditions sh
muscle in experiment 1 (B). For stringency, 3 conditions with changes in protein express
value < 0.05 and  2 unique peptides used for quantitation). C26 þ PBS vs control (a), C2
based heat map was drawn by implementing average linkage and the Spearman rank co
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The recombinant fusion protein was produced and purified as
described earlier [12]. In summary, the ectodomain of human ACVR2B
was fused with a human IgG1 Fc domain and expressed in Chinese
hamster ovary cells grown in a suspension culture. The final injected
protein is close to that originally generated by Lee and colleagues [13].
2.6. Tissue collection
On day 11 of the experiments, the mice were anaesthetised after an
overnight ad libitum state by an i.p. injection of ketamine and xylazine
(Ketaminol and Rompun, respectively), and euthanised by cardiac
puncture followed by cervical dislocation. Tissue samples were rapidly
excised, weighed, and snap-frozen in liquid nitrogen.
2.7. Muscle protein synthesis: in vivo surface sensing of translation
In experiment 2, muscle protein synthesis was analysed by using the
surface sensing of translation (SUnSET) method [12,20,21]. Briefly, on
day 11, after C26 cell inoculation, mice were injected i.p. with
0.04 mmol/g puromycin (Calbiochem, Darmstadt, Germany) dissolved
in 200 ml of PBS. Tibialis anterior (TA) muscle was isolated, weighed,
and snap-frozen in liquid nitrogen at 30 min after puromycin
administration.
2.8. Sample preparation and quantitative label free proteomics
analyses
Frozen muscle samples from experiment 1 (n ¼ 7 per group) were
thawed on ice; subsequently, they were homogenised in 2% SDS/
0.1 M Tris pH 8/0.05 M DTT at room temperature by using tissue
homogeniser. The homogenate was heated for 10 min at near 100 C
and cleared by centrifugation at 14 000 rpm (w20 800 g) for 15 min.
The protein concentration was determined by using the nanodrop
technique; 10 mg of total protein was digested, using a modified FASP
protocol [22]. To quantitatively assess the proteomics data, we used
data independent acquisition-nano-LC-HDMSE measurements as
described in literature [23,24]. Database searches were conducted
against UniProtKB/Swiss-Prot reviewed mouse (release 2017_16956
entries), with the ion accounting algorithm and by using the following
parameters: peptide and fragment tolerance, automatic; maximumay 0, and sACVR (5 mg/kg) or PBS vehicle were administered on days 11, 7, 3, 1,
experiment 2, sACVR (10 mg/kg) or PBS was injected only on days 6 and 9 after C26 cell
owing proteins with the strongest response to cancer and anti-cachexia treatment in
ion displaying only high fold change ratios are visualised (FC>j2.0j, FDR corrected p
6 þ sACVR/b vs C26 þ PBS (b) and C26 þ sACVR/c vs C26 þ PBS (c). An expression-
rrelation distance measure by using Heatmapper.
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
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7; minimum fragment ions matches per peptide 3; minimum
unique peptide matches per protein 1; digest enzyme-trypsin;
missed cleavages allowed - 2; fixed modification - carbamidomethy-
lation C; variable modifications - deamidation (N/Q) and oxidation of
methionine (M); and false discovery rate, FDR <4%. The quality of the
proteomic data was evaluated by PCA and by drawing a heatmap
(Heatmapper; www.heatmapper.ca) [25] of all of the quantified pro-
teins confirming the condition-specific clustering of the data according
to the study groups.
2.9. Database mining of proteomics data
Relative protein quantification between samples using precursor ion
intensities was performed with Progenesis QI Informatics for Pro-
teomics software (Version 3.0, Nonlinear Dynamics/Waters). To iden-
tify differentially expressed proteins (DEPs), P values (by ANOVA) and
fold change (FC) were set to <0.05 and > j1.3j, respectively. The
quantification was performed based on 2 unique peptides. The
filtered, false discovery rate (FDR < 0.05) corrected lists served as
inputs into Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Red-
wood City, CA; www.ingenuity.com).
2.10. Protein extraction and Western blotting
TA muscle (n ¼ 7e8 per group in experiment 1 and n ¼ 5e6 in
experiment 2) was homogenised in ice-cold buffer with proper pro-
tease and phosphatase inhibitors [4,12] and centrifuged at 10 000 g
for 10 min at þ4 C except for the SUnSET protein synthesis mea-
surements, where samples were centrifuged at 500 g for 5 min. Total
protein content was determined by using the bicinchoninic acid protein
assay (Pierce, Thermo Scientific) with an automated KoneLab device
(Thermo Scientific). Muscle homogenates containing 30 mg of protein
were solubilised in Laemmli sample buffer and heated at 95 C to
denature proteins, separated by SDS-PAGE, and transferred to PVDF
membrane, followed by overnight probing with primary antibodies
at þ4 C. Muscle proteins were visualised by enhanced chem-
iluminescence using a ChemiDoc XRS or ChemiDoc MP device (Bio-
Rad Laboratories) and quantified with Quantity One software version
4.6.3 (Bio-Rad Laboratories, Hercules, California, USA) or with Image
Lab software (version 6.0; Bio-Rad Laboratories), respectively. In the
case of puromycin-incorporated proteins, the intensity of the whole
lane was quantified. Ponceau S staining and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, ab9485: Abcam, Cambridge,
USA) were used as loading controls, and the muscle protein level
results were normalised to the mean of Ponceau S and GAPDH
(experiment 1) or to the overall intensity on stain-free gels (experiment
2). To assess serum proteins, samples (n ¼ 7e9 per group) were
diluted 1:4, and the results were normalised to the total protein in-
tensity on the membrane by using stain-free gels. Primary antibodies
were against serpin family A member 3n (Serpina3n, AF4709: R&D
Systems, Minneapolis, USA), p-STAT3 at Tyr705, total STAT3, p-ACC at
Ser79, p-Akt at Ser473 and total Akt (Cell Signalling Technology, Dan-
vers, USA), and fibrinogen (Abcam ab27913, Cambridge, UK).
2.11. RNA extraction, cDNA synthesis, and quantitative real-time
PCR
Total RNA was extracted from gastrocnemius samples (n ¼ 7e8 per
group) by using QIAzol and purified with the RNeasy Universal Plus kit
(Qiagen) according to manufacturer’s instructions, resulting in high-
quality RNA. RNA was reverse transcribed to complementary DNA
(cDNA) with the iScriptTM Advanced cDNA Synthesis Kit (Bio-Rad
Laboratories) according to kit instructions. Real-time qPCR was4 MOLECULAR METABOLISM 41 (2020) 101046  2020 The Author(s). Published by Elsevier Gperformed in triplicate according to standard procedures by using iQ
SYBR Supermix (Bio-Rad Laboratories) or Maxima SYBR Green qPCR
Master Mix (2x; Thermofisher Scientific) with CFX96 or CFX384
Touch Real-Time PCR Detection Systems and CFX Manager soft-
ware (Bio-Rad Laboratories), respectively. Data analysis was con-
ducted by using the efficiency corrected DDCt method. Based on the
lowest variation between and within the groups of the potential
housekeeping genes (Rn18S, Gapdh, 36b4, Hprt or Tbp), 36b4 or the
mean of 36b4 and Hprt was chosen. Primers used are listed in Sup-
plementary methods (Table S1).
2.12. NADþ metabolism and mitochondrial in situ analyses
NADþ and NADH were measured from gastrocnemius muscle (n ¼ 6
per group) by using slightly modified conventional colorimetric enzymatic
assays (see NADmed https://www.helsinki.fi/en/researchgroups/
mitochondrial-medicine/nadmed). The activity of main cellular NADþ
consumers, poly (ADP-ribose) polymerases (PARPs) was determined
from gastrocnemius muscle with the HT Colorimetric PARP/Apoptosis
Assay Kit (Trevigen, Inc., Gaithersburg, MD, USA) according to manu-
facturer’s instructions (n ¼ 5e6 per group).
For mitochondrial activity in situ analysis, serial cross-sections (8 mm)
from TA muscle were cut on a cryomicrotome (at 25 C; experiment
1, encompassing mice from CTRL, C26 þ PBS and C26 þ sACVR/c
groups). Mitochondrial activity was investigated by assessing the in
situ activity of succinate dehydrogenase (SDH, complex II) and cyto-
chrome c oxidase (COX, complex IV) from frozen TA muscle sections by
using histochemistry. Cross-sectional images were digitally captured
by using a Zeiss Axioplan 2 light microscope (Carl Zeiss AG, Germany)
with a ProgRes C7 camera and ProgRes CapturePro 2.9.0.1 software
(Jenoptik AG, Germany). Two fields-of-view per muscle cross-section
were captured with a 5 magnification. A sample was excluded if
cutting of the cross-section was unsuccessful (resulted in n¼ 5e7 per
group). The COX and SDH in situ activities were analysed with Fiji/
ImageJ (NIH, Bethesda, MD, USA) plugin Trainable Weka Segmentation
[26]. Image resolution was reduced to 1/4 of the original because of
the computational power required for analysis. Regions of interest
were determined separately for each image and, after splitting chan-
nels, applied to green channel images to obtain optical density values
of different fibre types. Optical density was assessed from all fibres
and from high COX and high SDH fibres. Muscle distribution of
mitochondria-rich, high SDH and COX fibres was calculated by using
the ImageJ plugin Cell Counter and represented as percentage of high
optical density fibres from all fibres.
2.13. Flow cytometry analysis to characterise splenomegaly in
cancer
In the second experiment, the spleens of mice derived from 3
experimental groups (n¼ 6e8 per group) were harvested under sterile
conditions, and single cell suspensions were prepared by gently
pressing the minced spleens through 70 mm cell strainers. The total
number of cells was calculated by counting the cell concentration by
using a Beckton Dickinson Accuri C6 flow cytometer. Ten6 cells were
then incubated with 0.4 mg/ml RNase A for 30’ and stained with
18 mg/ml propidium iodide to distinguish between erythrocytes and
nucleated cells and assess the percentage of proliferating cells.
2.14. Statistical analysis
Analyses (for proteomics analyses details, see above) were conducted
with a general linear model ANOVA or KruskalleWallis test and then a
two-tailed unpaired Student’s t test or ManneWhitney U test,
respectively, when appropriate. Planned comparisons in all analysesmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: Ingenuity pathway analysis reveals pathways and upstream regulators affected in muscle by cancer and anti-cachexia treatment in experiment 1. Canonical pathways
analysis (A). Pathways with significant z-scores (>j2j) in one of 3 comparisons are presented, and if available, z-scores of those pathways are also shown from other comparisons.
Heat map representation (B) of OXPHOS proteins with largest differential changes in their expression, in 3 comparisons: (a) C26 þ PBS vs control, (b) C26 þ sACVR/b vs
C26 þ PBS, and (c) C26 þ sACVR/c vs C26 þ PBS. The criteria used for assessment were as follows: fold change, FC>j1.3j, FDR corrected p value < 0.05, and 2 unique
peptides used for quantitation. An expression-based heat map using average linkage and the Spearman rank correlation distance measures. Upstream analysis pinpointing
upstream regulators predicted to be suppressed (C) or activated (D) in C26 þ PBS vs CTRL comparison (z-score >j2j) and if available, z-scores of those pathways are also shown
from other comparisons. Phosphorylated ACC at ser79 as a proxy for AMPK activation (p-ACC; E) and p-Akt at Ser473 as a proxy for mTORC2 activation (F). * ¼ P < 0.05 using a
two-tailed unpaired Student’s t test.were CTRL vs C26 þ PBS and within TB-mice, either sACVR/c or
sACVR/b (or sACVR in the second experiment) vs C26 þ PBS and
sACVR/c vs sACVR/b. When no clear effect of the sACVR administration
was observed, the C26 cancer effect was analysed by pooling C26
groups vs CTRL to simplify the results and the figures. Pearson’s
correlation coefficient was used to assess the correlations. The level of
significance was set at P < 0.05. Data were expressed as
means  SEM if not otherwise mentioned. Statistical analyses were
performed with IBM SPSS Statistics version 24 for Windows (SPSS,
Chicago, IL) and with GraphPad Prism 8.0.
3. RESULTS
3.1. Characterisation of muscle proteome
Previously, we demonstrated that C26 cell inoculation resulted in
muscle and fat wasting. Treating these TB-mice with sACVR before
and after tumour formation prevented muscle loss and prolonged
survival without affecting tumour size [4]. In this study, using label free
proteomics, we identified 1232 proteins extracted from the murine
muscles of these mice [4]. Notably, 876 proteins were quantified,
followed by the exclusion of proteins considered contaminants, for
example, blood haemoglobins or skin keratins (Table S2). The features
of all groups were assessed by principal component analysis (PCA),
which demonstrated a good group separation for TB and control mice
(for a summary, see the panels in Figure S1). PCA also revealed 2
biological outliers that we excluded from subsequent analyses,
resulting in n ¼ 6e7 mice per group. We identified 119 DEPs in PBS-MOLECULAR METABOLISM 41 (2020) 101046  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.comtreated TB-mice. Among these, 53 proteins exhibited a higher
expression level in TB-mice, and 66 were downregulated.
sACVR injection resulted in increased muscle size [4], accompanied by
126 DEPs (53 upregulated and 73 downregulated) with the prophy-
lactic and continued (sACVR/c) administration, and by 117 DEPs (58
up- and 59 downregulated in their expression) in the prophylactic/
discontinued (sACVR/b) administration, respectively, when compared
to PBS-treated TB-mice. For the purpose of stringency, only the most
altered proteins (FC > j2j) are presented in Figure 1, and the com-
parisons between the administration modalities are in Table S2.
3.2. Pathway analysis reveals decreased mitochondrial OXPHOS
signature in TB-mice: a response attenuated in sACVR-treated mice
Canonical pathway analysis of DEPs revealed a signature of decreased
mitochondrial oxidative phosphorylation (OXPHOS) in the PBS-treated
TB-mice (Figure 2A). Eighteen DEPs within this pathway included
subunits of OXPHOS complex I (NADH: ubiquinone oxidoreductase),
complex II (succinate dehydrogenase, SDH), complex III (ubiquinol-
cytochrome c reductase), complex IV (cytochrome c oxidase, COX), and
complex V (ATP synthase), suggesting a wide-spectrum down-
regulation of OXPHOS proteome (OXPHOSome; Figure 2B). This
downregulation was in part (several proteins of CI-IV and ATP synthase
subunits) prevented by sACVR/b (7 DEPs significantly upregulated
compared to C26þPBS) and sACVR/c administration (12 DEPs upre-
gulated vs C26þPBS), without an observable difference between
sACVR/c and sACVR/b (Figure 2B). TB-mice also exhibited a consistent
decrease in the expression of mitochondrial TCA cycle proteins (5 outan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 5
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synthase activity in the same TB-mice [4]. However, the blocking of
ACVR ligands had no marked effect on the TCA cycle (Figure 2A).
To further understand how the altered OXPHOSome signature affects
mitochondrial metabolism, we determined in situ activities of complex
II (SDH) and complex IV (COX) from the CTRL, C26þPBS, and
C26þsACVR/c groups. In line with the OXPHOS, in some results
showing complex II protein subunit downregulation, the percentage of
muscle fibres endowed with high SDH activity (and thus mitochondria-
rich fibres) significantly decreased in the PBS-treated TB-mice, and
this decrease was not significant in mice administered by continued
sACVR/c (Figure 3A). Different administration protocols did not induce
changes in total SDH and COX activities (Figure S2) or in the per-
centage of muscle fibres with high COX activity (Figure 3B). In sum-
mary, decreased in situ SDH activity in TB-mice validated dysregulated
OXPHOSome in cancer cachexia.
3.3. Decreased oxidative and anabolic signalling in TB-mice
predicted by upstream factor analysis, the latter response rescued
by sACVR
Unbiased upstream-regulator analysis suggested possible upstream
regulators to explain the dysregulated mitochondrial signature
(Figure 2C,D). More explicitly, it predicted that transcriptional regula-
tory proteins important for muscle mitochondrial biogenesis, OXPHOS
and fatty acid oxidation, such as peroxisome proliferator-activated
receptor gamma coactivator 1 alpha, and beta (PPARGC1A and
PPARGC1B, namely, PGC-1a/b) [27], peroxisome proliferator-activated
receptor-alpha (PPARA, i.e., PPARa) [28], and surprisingly, AMP-
activated protein kinase (AMPK) [29] are also significantly sup-
pressed (i.e. reduced activation, z-score< j2j) in TB-mice (Figure 2C).
However, phosphorylated ACC at Serine79 status, often used as a proxy
for AMPK activation, did not confirm suppressed AMPK-signalling in
cachexia (Figure 2E). Among predicted upstream regulators, PGC-1a
and PGC-1b were rescued by sACVR (Figure 2C).
Related to the decreased muscle mass in TB-mice and its treatment by
continued sACVR administration [4], the reduced activation of insulin
receptor (INSR) was predicted to be strongly linked to the C26þPBS vs
CTRL scenario (a consistent decrease in all 22 DEPs in the dataset forA
Figure 3: Muscle mitochondrial activity in situ is in part altered in cancer in experiment 1.
tailed unpaired Student’s t test.
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tion fully restored the activation of INSR in the same analysis
(Figure 2C). The predicted upstream regulators activated in TB-mice
are presented in Figure 2D. Connected to this pathway is the main
muscle size regulating hub, mTORC1, which was shown to be sup-
pressed in TB-mice and rescued by sACVR [4]. Surprisingly, Rictor,
which refers to a mechanistic target of rapamycin complex 2
(mTORC2), was predicted by IPA to be strongly activated in PBS-
treated TB-mice, and this response was prevented specifically in
sACVR/c treated mice (Figure 2D). The prediction implies that activa-
tion of mTORC1 and mTORC2 is regulated in an inversed manner in
cachexia and after the blocking of activin receptor ligands. Therefore,
phosphorylated Akt at Serine473 status, a standard proxy for mTORC2
activation, was analysed. However, the result of this analysis did not
confirm activated mTORC2-signalling in cachexia (Figure 2F).
3.4. Disturbed NADþ homeostasis in TB-mice is rescued by the
continued sACVR administration
NADþ metabolism is crucial for mitochondrial oxidative metabolism.
Namely, the NADþ/NADH redox couple regulates the activity of the TCA
cycle and OXPHOS, and the gene expression and activity of sirtuin 1
(Sirt1), the key inducer of PGC-1a activity [30]. Therefore, oxidised and
reduced concentrations of NADþ were assessed. We observed that the
levels of both oxidised (NADþ) and reduced NAD (NADH) decreased in
PBS-treated TB-mice (P < 0.05), and unlike sACVR/b, sACVR/c
restored the depleted NADþ levels; for NADH, this effect was not
statistically significant (Figure 4A,B).
To uncover the mechanism behind NADþ depletion, we next analysed
NADþ consumption and biosynthesis pathways in TB-mice. Given that
the activity of the major cellular NADþ consumers, PARPs, remained
unchanged, the NADþ depletion in TB-mice is unlikely to result from
PARP-dependent NADþ utilisation (Figure 4C). Notably, the expression
analysis of the main muscle genes involved in NADþ biosynthesis
pathways (salvage and PreisseHandler pathways) revealed a strongly
diminished muscle isoform of nicotinamide riboside kinase (Nrk), Nrk2,
in PBS-treated TB-mice, and sACVR/c completely rescued it (P< 0.05;
Figure 4D). Similar to NADþ levels, the sACVR/b administration mo-
dality demonstrated no effects on Nrk2 expression (Figure 4D). ByB
Percentage of fibres with high SDH (A) or COX (B) activities. * ¼ P < 0.05 using a two-
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Figure 4: NADþ and its regulators are affected in TB-mice and in part rescued by anti-cachexia treatment in experiment 1. Contents of NADþ (A) and NADH (B), and PARP activity
(C). Gene expression of the regulators of NADþ biosynthesis (D). * ¼ P < 0.05, ** ¼ P < 0.01, and *** ¼ P < 0.001 when using a two-tailed unpaired Student’s t test.contrast, the expression of the ubiquitously expressed isoform, Nrk1,
was similar in all groups (Figure 4D). The expression of other enzymes
of the NADþ biosynthesis pathway, namely, nicotinamide phosphor-
ibosyltransferase (Nampt), nicotinamide adenylyl transferase 3
(Nmnat3), and nicotinate phosphoribosyltransferase (Naprt) increased
in PBS-treated TB-mice, a feature that was normalised by sACVR
(Figure 4D).
The de novo NADþ biosynthesis pathway is considered to operate at a
low level in skeletal muscle and thus may have low physiological
significance. Nevertheless, we observed increased tryptophan 2,3-
dioxygenase (Tdo) and quinolinate phosphoribosyltransferase (Qprt)
expression in the PBS-treated TB-mice, and these responses tended to
be preserved in the sACVR-treated condition (Figure S3). Downstream
to NADþ, TB-mice demonstrated downregulation of NADþ dependent
Sirt1 (P ¼ 0.053, Figure 4D), which acts as an important protein
deacetylase, protecting cells from metabolic stress. In line with the
NADþ and Nrk2 results, Sirt1 expression was rescued by sACVR/c, and
less so by sACVR/b (Figure 4D). Overall, our data suggest that cancer
cachexia is characterised by muscle NADþ deficiency which can be
restored by sACVR when administered before and after tumour
injection.
3.5. Therapeutic ACVR ligand blockade restores muscle mass,
protein synthesis, NAD⁺ levels and Nrk2
In addition to the prophylactic and/or prophylactic and continued ACVR
blocking, we next conducted a more translatable experiment in which
the sACVR administration was initiated after tumour formation. We
observed that sACVR treatment increased BM (Figure 5A) and rescued
the decrease in muscle mass (Figure 5B) and protein synthesis in TB-
mice (Figure 5C) without affecting the tumour growth (Figure 5B). We
also replicated the findings of experiment 1 and showed that muscleMOLECULAR METABOLISM 41 (2020) 101046  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.comNADþ is depleted in C26 TB-mice even when cachexia is very mild
(Figure 5D), and this was accompanied by decreased Nrk2 expression
(P¼ 0.052; Figure 5E). Therapeutic sACVR treatment restored levels of
NADþ (Figure 5D), and a similar trend was observed for Nrk2
(P ¼ 0.095; Figure 5E); both results are in line with the results of
sACVR/c administration. To support the findings from experiment 1, we
also replicated the results of Nmnat3 and Naprt gene expression but
not of Nampt (Figure 5E). However, the expression of Nrk1 and Sirt1
was very low and thus not quantified. In summary, these data validated
the tumour-effects observed in a previous experiment and showed that
muscle NADþ deficiency can be restored by exposure to therapeutic
sACVR.
3.6. Pathway and upstream analyses reveal acute phase response
in TB-mice
Pathway analysis predicted involvement and upregulation of acute
phase proteins (APPs) reflecting acute phase response (APR) in cancer
(Figures 2A and 6A). Corresponding upstream analysis indicated that
activated STAT3 (P ¼ 2.17*107, Z-score 1.45, not shown) may
represent a regulator for this response, as shown by Bonetto et al. [31].
Subsequently, Western blotting analysis confirmed increased phos-
phorylation of STAT3 in TB-mice (Figure 6B). The STAT3 signalling
pathway is downstream to IL-6 and MCP-1, both being elevated in the
serum of TB-mice [4], which may connect mitochondrial dysfunction to
muscle cachexia [2].
3.7. APP Serpina3n, the most altered protein in TB-mice, is
associated with the loss of BM but not affected by the anti-cachexia
treatment
Among identified DEPs within the APR pathway, Serpina3n (human
orthologue of Serpina3, also known as Alpha-1-antichymotrypsin)an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 7
Figure 5: Anti-cachexia treatment after tumour inoculation (experiment 2) reveals increased body mass, muscle masses, and muscle protein synthesis and repleted NADþ.
Changes in body mass (BM; A), tissue masses (B), muscle protein synthesis (C), contents of NADþ (D), and gene expression of the regulators of NADþ biosynthesis (E) in control
mice and in mice treated with sACVR or PBS. Epi. fat ¼ epididymal fat pad. * ¼ P < 0.05, ** ¼ P < 0.01, and *** ¼ P < 0.001 when using a two-tailed unpaired Student’s t
test.
Original Articlerepresented the most strongly upregulated protein (Figures 1B and 6A),
whose increased expression was validated in cachectic muscle by
Western blotting (Figure 6C). Elevated Serpina3n levels were also
observed in the serum of TB-mice (Figure 6D). The increase in Ser-
pina3n protein was probably due to the transcriptional regulation of the
gene because the level of muscle mRNA expression of Serpina3n
increased in TB-mice (Figure S4), and it correlated well with the
Serpina3n protein level (r¼ 0.67, P¼ 0.001). Serpina3n was higher in
the sACVR/b group than in the sACVR/c (P < 0.001) group, without an
observable difference when compared with PBS-treated TB-mice
(Figure 6A,C). A similar effect was traced on the qPCR analysis
(Figure S4), demonstrating that Serpina3n protein and mRNA levels are
most upregulated in a group of mice with the strongest decrease in BM
during the last days before the tissue collection [4].
These results and the earlier evidence [32] suggest that Serpina3n
may represent a biomarker related to changes in muscle/BM. Indeed,
muscle Serpina3n protein strongly correlated with the loss of BM at 9e
11 days after tumour cell engraftment (r ¼ 0.77, P < 0.001) in TB-
mice (Figure 5E). A similar observation was made at the mRNA level8 MOLECULAR METABOLISM 41 (2020) 101046  2020 The Author(s). Published by Elsevier G(r ¼ 0.84, P < 0.001, Figure S5A). At this time point, the loss of BM
predicted survival (Cox regression: B ¼ 0.90, P < 0.001) in another
group of mice [4]. The proteomics result was validated by Western
blotting in TB-mice (r ¼ 0.64, P < 0.001, Figure 6E). In serum
(r ¼ 0.69, P < 0.001) and in the liver (r ¼ 0.82, P < 0.001),
Serpina3n levels also correlated with BM loss at the same time point
(Figure S5A). These results demonstrate that high Serpina3n expres-
sion (at the mRNA and protein level) is related to a significant loss of
BM in TB-mice.
The gene expression of other APPs, namely, Saa1 and Fibrinogen G
(Figure S4), as well as serum Fibrinogen, were elevated in TB-mice
(Figure S5B). Unlike Serpina3n, serum Fibrinogen correlated with
BM loss only when all mice were included (r¼0.58, P< 0.001), but
not in TB-mice (r ¼ 0.32, P ¼ 0.154; Figure S5B). In skeletal
muscle, APP components were not affected by sACVR (Figure 6A).
We subsequently conducted a correlation analysis including all pro-
teins identified in muscle proteomics. Among those, Serpina3n clearly
correlated most strongly with the loss of BM at 9e11 days after
tumour cell engraftment followed by fibrinogen G (data not shown).mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 6: APR is activated in TB-mice independent of anti-cachexia treatment. Heat map representation of differential proteome changes of APPs in experiment 1. The analyses in
3 conditions with the highest fold change ratio are shown (FC>j1.3j, FDR corrected P value < 0.05 and  2 unique peptides used for quantitation), namely: (a) C26 þ PBS vs
control, (b) C26 þ sACVR/b vs C26 þ PBS, and (c) C26 þ sACVR/c vs C26 þ PBS. An expression-based heat map is using average linkage and the Spearman rank correlation
distance measures (A). Phosphorylated STAT3 (p-STAT3; B) and Serpina3n quantifications in muscle (C) and in serum (D). Correlation analysis of Serpina3n in the muscle,
quantified either by label free proteomics or with Western blotting and cachexia (a decrease in the body mass, BM; E). Serpina3n in muscle (F) and in serum (G) in mice treated with
sACVR/PBS after tumour cell inoculation in experiment 2. * ¼ P < 0.05, ** ¼ P < 0.01, and *** ¼ P < 0.001 when using a two-tailed unpaired Student’s t test.3.8. Cachexia-associated Serpina3n reflects the inflammatory
state
In the second experiment, we replicated the findings of increased
muscle (Figure 6F) and serum (Figure 6G) Serpina3n independently of
sACVR treatment, even though sACVR rescued cachexia and muscle
protein synthesis. Furthermore, muscle Serpina3n correlated with BM
loss in TB-mice only when sACVR-treated mice (with stronglyMOLECULAR METABOLISM 41 (2020) 101046  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.comincreased BM, muscle mass, and muscle protein synthesis) were
excluded from the analysis (Figure S6). To further analyse the impact of
inflammation in TB-mice and whether Serpina3n reflects on it, we
analysed the spleen size and its morphology. Spleen size increased in
TB-mice, and this was not affected by the sACVR treatment
(Figure S7). To investigate the C26-induced spleen enlargement,
namely, splenomegaly in more detail, a flow cytometry analysis wasan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 9
Original Articleconducted, which demonstrated the process that stemmed from both
increased erythrocyte engulfment and white blood cell proliferation
(Figure S7). Spleen mass, as well as serum IL-6, correlated with
muscle Serpina3n (Figure S6).
4. DISCUSSION
In this study we characterised the muscle proteome of TB-mice with or
without anti-cachexia treatment. Our proteomics results demonstrated
a reduction in the expression of proteins implicated in OXPHOSome, a
finding further corroborated by measurements pinpointing dysregu-
lated NADþmetabolism and alterations in NADþ biosynthesis including
downregulation of Nrk2 in cancer cachexia. These changes were
rescued by sACVR when administered to TB-mice. In subsequent
experiments we demonstrated that sACVR treatment that commenced
after tumour formation prevented a cancer-induced decrease in
muscle protein synthesis and NADþ but not splenomegaly. Finally, we
established evidence for acute phase protein Serpina3n as the most
consistent predictor of untreated cachexia in murine muscle proteome
but not as a generic marker of alterations in muscle mass.
The decrease in the OXPHOSome, the lowered expression of components
in the TCA-pathway, and the low percentage of muscle fibres with high
SDH activity in TB-mice support the published observations of mito-
chondrial dysfunction in cancer cachexia demonstrated by using prote-
omics [33], transcriptomics [34], and mitochondrial oxidative enzyme
activity analyses [4,35]. However, based on Western blot assay, the
protein content of few OXPHOS proteins has also been reported to remain
relatively unaltered in cachectic TAmuscle [4]. In cancer cachexia,muscle
mitochondrial dysfunction may occur in part through cytokine-signalling
such as IL-6 e STAT3 axis [2], confirmed by this study; alternatively or
complementary to this, reduced physical activity observed in these TB-
mice [4] may contribute to the process of dysregulated mitochondria
[2] that per se may be sufficient to induce muscle atrophy [36]. Utilising
proteomics, we demonstrated that blocking ACVR ligands attenuated
these changes in OXPHOSome, but no significant differences were
observed in the response between the administration modalities. Previ-
ously, blocking ACVR ligands has either had no effect [15] or even
diminished mitochondrial oxidative capacity [14,37,38], and decreased
OXPHOS-related protein expression inmuscle [39]while inducing fast and
glycolytic transformation [40]. However, blocking ACVR ligands has also
resulted in positive outcomes in various disease, injury, and ageing
models [4e6,15,40e42]. Our results imply that blocking ACVR ligands
can have context-dependent effects on muscle oxidative metabolism.
Whether the rescue of OXPHOSome is linked to improved survival [4]
requires further research.
As predicted by the upstream-regulator analysis, the diminished ac-
tivities of PGC-1 a/b and PPARa may contribute to the global OXPHO-
Some alterations in cachectic muscle. Their deletion causes impairment
of mitochondrial OXPHOS transcription and oxidative metabolism
especially in stress conditions in mice [27,28]. We have observed a
decrease in muscle PGC-1a in mice inoculated with C26 cells [35], and
a similar tendency was observed in these mice, in TA muscle [4].
Moreover, dysregulated NADþ/sirtuin metabolism may contribute to the
altered OXPHOSome signature in cachectic muscle. Notably, both oxi-
dised and reduced NADþ levels were significantly lowered in untreated
TB-mice. In addition, a moderate decrease in the key regulator of
muscle mitochondrial oxidative metabolism and stress defence, NADþ
-dependent Sirt1, was observed in cancer cachexia, as was shown in
TB-mice in relation to the severity of cancer cachexia [43]. The
continued and post-tumour ACVR treatment replenished NADþ levels,
and continued administration also normalised the expression of Sirt110 MOLECULAR METABOLISM 41 (2020) 101046  2020 The Author(s). Published by Elsevier Gsimilar to the predicted activities of its downstream targets PGC-1a/b.
NADþ depletion and a subsequent disturbance in cellular redox status
can alter the function of various pathways such as mitochondrial energy
production, cellular signalling, chromatin modulation, DNA repair, ROS
defence, inflammation and immune responses, and circadian rhythm
[44]. Previously, we demonstrated that sACVR altered redox balance and
offered antioxidant protection in the muscles of these TB-mice by
restoring the decreased levels of reduced glutathione (GSH) [17].
Therefore, sACVR can enhance the function of a wide range of cellular
processes. In line with our results, several animal studies have
demonstrated that NADþ boosting is a promising therapy option to treat
diseases with multifactorial pathology, for example, muscle dystrophy
and myopathy, obesity, diabetes, fatty liver, and cardiac diseases [44].
Further studies should investigate whether NADþ boosters offer an
advantage in cancer cachexia. Overall, our work establishes a novel
finding of NADþ depletion in cancer cachexia, which can be restored by
sACVR treatment in TB-mice.
This study also revealed that NAD⁺ depletion in cachectic muscle is
associated with the altered expression of genes involved in NAD⁺
biosynthesis pathways but not with enzymatic activities of NAD⁺ con-
sumers. Namely, the decline in NADþ levels probably did not originate
from the increased activity of PARPs, the major NADþ consumers in cells
[45], because the total PARP activity was unaltered in TB-mice. The
analysis of NADþ biosynthesis proposes Nrk2 (Nmrk2), an enzyme
involved in the salvage pathway, is potentially associated with low
muscle NADþ content in cancer cachexia. By contrast, the gene
expression of several other enzymes in the NADþ biosynthesis pathway
was elevated in PBS-treated TB-mice. These findings are puzzling
because the deletion of Nrk2 has not been demonstrated to affect
muscle NADþ levels because Nrk2 is redundant with other proteins such
as Nrk1 in the NADþ salvage pathway [46,47]. Thus, the question raised
is whether muscle Nrk2 downregulation results in a depletion of NADþ
levels in cancer cachexia or whether Nrk2 downregulation is related to
its other functions such as modulation of muscle mass. Another question
raised here is whether Nrk2 downregulation is related to its other
functions such as regulation of muscle fibre size, as reported in the
literature [47]. Nrk2 deficiency has also been shown to increase muscle
expression of cytokine Il-15, a potent regulator of muscle growth. We,
however, did not observe major changes in muscle Il-15 (Figure S3).
Overall, our studies revealed downregulation of Nrk2 in cancer cachexia
and its restoration by sACVR. Nevertheless, further research should
investigate the regulation of Nrk2 via TGF-b superfamily cytokines and
the role of Nrk2 in the maintenance of muscular NAD⁺ pool during
pathological conditions such as cancer cachexia. Further research
should also examine whether the myostatin/activin blockage repletes
NADþ and Nrk2 deficiencies via direct action or by interfering with
cachexia-altered signalling events.
APR is an early response in cancer belonging to the innate immune
system characterised by increased expression of positive APPs [48].
The APR protein Serpina3n belongs to a family of serine protease in-
hibitors. Serpina3n contains a signal peptide and is secreted into
C2C12 muscle cell media after atrophic stimuli (i.e. glucocorticoids)
[32], and in humans, it may be exported to blood through small ves-
icles [49], suggesting that Serpina3 (or Serpina3n) may indeed be a
myokine. As demonstrated in proteomics experiments, Serpina3n was
the most strongly associated protein with the loss of BM. Similarly,
elevated Serpina3n levels in plasma and liver strongly correlated with
cachexia. This occurred at a time point in which cachexia was pre-
dictive for a large variation in survival [4]. Our results are in accordance
with the results of human studies connecting increased APR with
compromised survival in cancer cachexia [50,51]. Although APR maymbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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assist in limiting host infection and tissue injury, its prolonged action
may further contribute to the severity of cachexia [51].
The research on C26-induced cachexia has described an elevated
expression of Serpina3n at mRNA [34] and protein [32] levels and that
Serpina3n is associated with muscle mass [32]. Our findings on Ser-
pina3n upregulation support these studies and also show that of the
whole muscle proteome, Serpina3n was the best predictor of cachexia
at a time point when cachexia predicts survival [32]. This finding,
however, does not necessarily imply that the protein is causally related
to cachexia or survival. To understand whether Serpina3n is influenced
by changes in muscle protein synthesis and mass, we modulated these
factors by treating TB-mice with sACVR after tumour inoculation and
thus only a few days before the mice were euthanised. This demon-
strated that muscle Serpina3n does not seem to represent a bona fide
marker of alterations in muscle mass because i) muscle Serpina3n also
increased in the sACVR-treated mice with a rescue of muscle mass, and
ii) muscle Serpina3n correlated with the loss of BM only when the
sACVR-treated mice were excluded from the analysis. Instead of being a
direct regulator of muscle mass, increased Serpina3n may have various
other effects. For instance, it correlated with spleen mass and serum IL-
6, another strongly altered responses in cancer, showing that Serpina3n
may reflect the inflammatory state in various tissues. The C26-induced
splenomegaly originated from erythrocyte engulfment and white blood
cell proliferation, both of which remained unaffected by sACVR
administered only after tumour cell injection. This finding does not
support our previous findings of splenomegaly mitigation after sACVR
administration also before tumour formation [4]. In addition, increased
muscle Serpina3n may also have localised effects in muscle extracel-
lular space such as evoking decreased activity of proteases and thus
protecting muscle from acute injury and muscle dystrophy [52]. This
putative, protective effect of Serpina3n is also of interest in C26-TB
mice, in which membrane abnormalities further accentuate muscle
wasting [53]. Surprisingly, Serpina3n also correlated with muscle Nrk2
(r ¼ 0.72 and 0.74 in all mice and in TB-mice, respectively,
P< 0.001, Figure S8) suggesting a possible connection of APR to Nrk2
downregulation.
In conclusion, our results reveal disturbed OXPHOSome and NADþ
metabolism as a molecular determinant of cancer cachexia, which
were rescued upon ACVR ligand blockade, depending on the used
administration modality. We also present evidence implicating Ser-
pina3n as a predictor of untreated cachexia but not as a generic
marker of alterations in muscle mass.
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